Immunomedics is launching a registrational Phase 3 study for patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2–) metastatic breast cancer, after failure of at least 2, and no more than 4, prior chemotherapy regimens for metastatic disease. For more information, please visit TROPICS-02.com.
Immunomedics is currently sponsoring an international Phase 3 clinical trial of sacituzumab govitecan in patients with relapsed triple-negative breast cancer who have previously received two or more therapies for their metastatic disease. For more information on this clinical trial, please visit tnbctrial.com
Immunomedics is recruiting for a Phase II trial of sacituzumab govitecan for patients with metastatic (Stage IV) urothelial cancer after failure of a platinum-based regimen and/or anti-PD-1/PD-L1 based therapies. For more information visit TrophyTrials.com
Compassionate Use Program
Immunomedics does not have a Compassionate Use Program for IMMU-132 at this time; however, patients with refractory/relapsed triple-negative breast cancer may be eligible for enrollment in the large ASCENT clinical trial (ClinicalTrial.gov Identifier: NCT02574455). Subjects are currently being recruited at 177 locations in the United States and Europe.